Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
INCY.MX
Strong BuyFull HouseAPPROVEIncyte Corporation · Healthcare · United States · $25.3B · Avg Vol: $42K/d
Incyte is a high-quality biotech compounder with strong clinical execution in specialized treatments. Its strategic expansion into Latin American markets through partnerships, combined with a diversified pipeline, positions it as a beneficiary of the shift toward specialized, patient-centric drug development.
COMPANY DESCRIPTION
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
FINANCIAL SUMMARY (MXN)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 58.2B | 63.4B | 72.7B | 88.2B | 14.8% | 99.8B | 101.9B | 107.4B | 10.4% |
| EPS (MXN) | 26.24 | 45.78 | 2.74 | 113.00 | 62.7% | 134.22 | — | — | — |
| Shares | 222.7M | 224.3M | 193.4M | 198.5M | -10.9% | 202.7M | — | — | — |
| Debt | 710.9M | 656.5M | 746.7M | 693.0M | -0.8% | 656.2M | — | — | — |
| Equity | 74.9B | 89.0B | 59.1B | 88.6B | 5.7% | — | — | — | — |
| Op CF | 16.6B | 8.5B | 5.8B | 24.2B | 13.4% | 33.9B | — | — | — |
| Inv CF | -1.3B | -3.6B | 2.7B | -1.8B | — | — | — | — | — |
| Fin CF | -13.6M | -343.5M | -34.7B | 1.7B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of INCY.MX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| INCY.MX | Incyte Corporation(you) | $25.3B | — | Hold |
| EXEL | Exelixis, Inc. | $13.5B | 98 | Strong Buy |
| HALO | Halozyme Therapeutics, Inc. | $12.0B | 95 | Strong Buy |
| TECH | Bio-Techne Corporation | $11.3B | 76 | Buy |
| REGN | Regeneron Pharmaceuticals, Inc. | $81.8B | 82 | Strong Buy |
| CORT | Corcept Therapeutics Incorporated | $12.3B | 71 | Buy |
| KRYS | Krystal Biotech, Inc. | $10.4B | 74 | Buy |
| RPRX | Royalty Pharma plc | $35.2B | 59 | Hold |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.3B | 100 | Strong Buy |
| BMRN | BioMarin Pharmaceutical Inc. | $12.5B | 65 | Buy |
Peer medians: ROE -30.7% · P/E 27.1x · Gross margin 58.3%